Clinical Trials Browser

Neoplasm Metastasis

Adenocarcinoma of Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Cholangiocarcinoma

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Small Cell Lung Carcinoma

Limited Stage Small Cell Lung Cancer

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Lung Neoplasms

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Adenocarcinoma, Stomach Neoplasms

Advanced Biliary Tract Carcinoma

Carcinoma, Hepatocellular, Liver Cirrhosis

Extensive Stage Small Cell Lung Cancer

Carcinoma, Hepatocellular

Non Small Cell Lung Cancer NSCLC

Carcinoma, Hepatocellular

Urinary Bladder Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Non-small-cell Lung Cancer Patients

Cholangiocarcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Leukemia, Lymphocytic, Chronic, B-Cell

Carcinoma, Ovarian Epithelial

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

Adenocarcinoma of Lung, Lung Neoplasms

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Neoplasm Metastasis

Cholangiocarcinoma

Esophageal Neoplasms

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Clinical Trials

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

CONVERGE

I-SPY

NeoCOAST-2

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

HAIC-quad

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

TIGOS-LS

DG-03

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

IPROC

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

TACTIC

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

TREMENDOUS-2

AUSTRAL

SLIDE-HCC

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

DIAMOND

ZENOBIA

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

WoO

VIRO-25

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Proton-STRIDE

ATRiBRAVE

PHOENIX

MOST plus

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

PALEO

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

DURVALUNG

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Photon-STRIDE

MATISSE

DUMELEP